Cargando…

Adagrasib, a KRAS G12C inhibitor, reverses the multidrug resistance mediated by ABCB1 in vitro and in vivo

BACKGROUND: Multidrug resistance (MDR) is a complex phenomenon that frequently leads to chemotherapy failure during cancer treatment. The overexpression of ATP-binding cassette (ABC) transporters represents the major mechanism contributing to MDR. To date, no effective MDR modulator has been applied...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Yuchen, Li, Cheukfai, Xia, Chenglai, Wah To, Keneth Kin, Guo, Zhixing, Ren, Chongyang, Wen, Lingzhu, Wang, Fang, Fu, Liwu, Liao, Ning
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9472360/ https://www.ncbi.nlm.nih.gov/pubmed/36104708 http://dx.doi.org/10.1186/s12964-022-00955-8

Ejemplares similares

Adagrasib: A landmark in the KRAS(G12C)‐mutated NSCLC
por: Tian, He, et al.
Publicado: (2022)

Reversal of ABCB1-related multidrug resistance by ERK5-IN-1
por: Wang, Fang, et al.
Publicado: (2020)

Synthesis of Adagrasib (MRTX849), a Covalent KRAS(G12C) Inhibitor Drug for the Treatment of Cancer
por: Chen, Cheng-yi, et al.
Publicado: (2023)

A Long Overdue Targeted Treatment for KRAS Mutations in NSCLC: Spotlight on Adagrasib
por: Brazel, Danielle, et al.
Publicado: (2022)

Evaluating the intracranial activity of adagrasib
por: Kotecha, Rupesh, et al.
Publicado: (2023)

Practical Guidance for the Management of Adverse Events in Patients with KRAS(G12C)-Mutated Non-Small Cell Lung Cancer Receiving Adagrasib
por: Zhang, Jun, et al.
Publicado: (2023)

Alectinib (CH5424802) antagonizes ABCB1- and ABCG2-mediated multidrug resistance in vitro, in vivo and ex vivo
por: Yang, Ke, et al.
Publicado: (2017)

Correction: Alectinib (CH5424802) antagonizes ABCB1- and ABCG2-mediated multidrug resistance in vitro, in vivo and ex vivo
por: Yang, Ke, et al.
Publicado: (2020)

First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With Advanced KRAS(G12C) Solid Tumors (KRYSTAL-1)
por: Ou, Sai-Hong Ignatius, et al.
Publicado: (2022)

Activity of Adagrasib (MRTX849) in Brain Metastases: Preclinical Models and Clinical Data from Patients with KRAS(G12C)-Mutant Non–Small Cell Lung Cancer
por: Sabari, Joshua K., et al.
Publicado: (2022)

Midostaurin Reverses ABCB1-Mediated Multidrug Resistance, an in vitro Study
por: Ji, Ning, et al.
Publicado: (2019)

Intracranial Efficacy of Adagrasib in Patients From the KRYSTAL-1 Trial With KRAS(G12C)-Mutated Non–Small-Cell Lung Cancer Who Have Untreated CNS Metastases
por: Negrao, Marcelo V., et al.
Publicado: (2023)

Reversal effect of FW-04-806, a macrolide dilactone compound, on multidrug resistance mediated by ABCB1 and ABCG2 in vitro and in vivo
por: Zhang, Zhiqiang, et al.
Publicado: (2019)

Lazertinib improves the efficacy of chemotherapeutic drugs in ABCB1 or ABCG2 overexpression cancer cells in vitro, in vivo, and ex vivo
por: Fan, Yingfang, et al.
Publicado: (2022)

Tetrandrine Interaction with ABCB1 Reverses Multidrug Resistance in Cancer Cells Through Competition with Anti-Cancer Drugs Followed by Downregulation of ABCB1 Expression
por: Liao, Dan, et al.
Publicado: (2019)

Uncaria alkaloids reverse ABCB1-mediated cancer multidrug resistance
por: Huang, Bao-Yuan, et al.
Publicado: (2017)

KRAS mutation: from undruggable to druggable in cancer
por: Huang, Lamei, et al.
Publicado: (2021)

Overexpression of ABCB1 Associated With the Resistance to the KRAS-G12C Specific Inhibitor ARS-1620 in Cancer Cells
por: Dong, Xing-Duo, et al.
Publicado: (2022)

A 20(S)-protopanaxadiol derivative PPD12 reverses ABCB1-mediated multidrug resistance with oral bioavailability and low toxicity
por: Wei, Shunfeng, et al.
Publicado: (2018)

Is adagrasib just another sotorasib?—or, should we differentiate their usage according to patients’ clinical presentation?
por: Oya, Yuko, et al.
Publicado: (2023)

Cetuximab enhanced the efficacy of chemotherapeutic agent in ABCB1/P-glycoprotein-overexpressing cancer cells
por: Wang, Fang, et al.
Publicado: (2015)

Polyoxypregnanes as safe, potent, and specific ABCB1-inhibitory pro-drugs to overcome multidrug resistance in cancer chemotherapy in vitro and in vivo
por: Wu, Xu, et al.
Publicado: (2021)

Bafetinib (INNO-406) reverses multidrug resistance by inhibiting the efflux function of ABCB1 and ABCG2 transporters
por: Zhang, Yun-Kai, et al.
Publicado: (2016)

Trametinib modulates cancer multidrug resistance by targeting ABCB1 transporter
por: Qiu, Jian-Ge, et al.
Publicado: (2015)

Distinct clinical and somatic mutational features of breast tumors with high-, low-, or non-expressing human epidermal growth factor receptor 2 status
por: Zhang, Guochun, et al.
Publicado: (2022)

Spectrum of MAP3K1 mutations in breast cancer is luminal subtype-predominant and related to prognosis
por: Li, Cheukfai, et al.
Publicado: (2022)

Olaparib Conjugates with Selenopheno[3,2-c]quinolinone Inhibit PARP1 and Reverse ABCB1-Related Multidrug Resistance
por: Makrecka-Kuka, Marina, et al.
Publicado: (2022)

Erdafitinib Antagonizes ABCB1-Mediated Multidrug Resistance in Cancer Cells
por: Feng, Weiguo, et al.
Publicado: (2020)

Fragment Optimization of Reversible Binding to the Switch II Pocket on KRAS Leads to a Potent, In Vivo Active KRAS(G12C) Inhibitor
por: Bröker, Joachim, et al.
Publicado: (2022)

A Novel Synthetic Dihydroindeno[1,2-b] Indole Derivative (LS-2-3j) Reverses ABCB1- and ABCG2-Mediated Multidrug Resistance in Cancer Cells
por: Guo, Chao, et al.
Publicado: (2018)

Antimicrobial Peptide Reverses ABCB1-Mediated Chemotherapeutic Drug Resistance
por: Luo, Xiaofang, et al.
Publicado: (2020)

Erastin Reverses ABCB1-Mediated Docetaxel Resistance in Ovarian Cancer
por: Zhou, Hai-Hong, et al.
Publicado: (2019)

Heterogenous and Low Expression of HER2 in Breast Cancer Overcome by DS-8201a in a Heavily Treated Patient: Case Report and Review of the Literature
por: Li, Cheukfai, et al.
Publicado: (2022)

Characterization of AKT Somatic Mutations in Chinese Breast Cancer Patients
por: Wen, Lingzhu, et al.
Publicado: (2021)

Isobavachalcone as an Active Membrane Perturbing Agent and Inhibitor of ABCB1 Multidrug Transporter
por: Palko-Łabuz, Anna, et al.
Publicado: (2021)

Characterization and tissue localization of zebrafish homologs of the human ABCB1 multidrug transporter
por: Robey, Robert W., et al.
Publicado: (2021)

Overcoming ABCB1-mediated multidrug resistance by transcription factor BHLHE40
por: Yin, Yongmei, et al.
Publicado: (2023)

PIK3CA somatic alterations in invasive breast cancers: different spectrum from Caucasians to Chinese detected by next generation sequencing
por: Jia, Minghan, et al.
Publicado: (2021)

Biallelic mutations in ABCB1 display recurrent reversible encephalopathy
por: Seo, Jieun, et al.
Publicado: (2020)

SuperNatural inhibitors to reverse multidrug resistance emerged by ABCB1 transporter: Database mining, lipid-mediated molecular dynamics, and pharmacokinetics study
por: Ibrahim, Mahmoud A. A., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_8hf4d3f46fvcg4utn8cf1i761m